Literature DB >> 17047148

Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation.

Peter W Collins1, Sybil Hirsch, Trevor P Baglin, Gerard Dolan, John Hanley, Michael Makris, David M Keeling, Ri Liesner, Simon A Brown, Charles R M Hay.   

Abstract

Acquired hemophilia A is a severe bleeding disorder caused by an autoantibody to factor VIII. Previous reports have focused on referral center patients and it is unclear whether these findings are generally applicable. To improve understanding of the disease, a 2-year observational study was established to identify and characterize the presenting features and outcome of all patients with acquired hemophilia A in the United Kingdom. This allowed a consecutive cohort of patients, unbiased by referral or reporting practice, to be studied. A total of 172 patients with a median age of 78 years were identified, an incidence of 1.48/million/y. The cohort was significantly older than previously reported series, but bleeding manifestations and underlying diseases were similar. Bleeding was the cause of death in 9% of the cohort and remained a risk until the inhibitor had been eradicated. There was no difference in inhibitor eradication or mortality between patients treated with steroids alone and a combination of steroids and cytotoxic agents. Relapse of the inhibitor was observed in 20% of the patients who had attained first complete remission. The data provide the most complete description of acquired hemophilia A available and are applicable to patients presenting to all centers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047148     DOI: 10.1182/blood-2006-06-029850

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  148 in total

1.  Autoimmune haemophilia.

Authors:  Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

Review 2.  Autoimmune hemophilia at rescue.

Authors:  Pier Mannuccio Mannucci; Flora Peyvandi
Journal:  Haematologica       Date:  2009-04       Impact factor: 9.941

Review 3.  Clinical use and the Italian demand for activated prothrombin complex and activated recombinant factor VII concentrates.

Authors:  Antonio Coppola; Annarita Tagliaferri; Gabriele Calizzani; Fabio Candura; Massimo Franchini; Carlo Ruosi; Giuliano Grazzini; Giovanni Di Minno
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

4.  Cautions and caveats to the treatment of acquired hemophilia A.

Authors:  Angela Huth-Kühne
Journal:  Haematologica       Date:  2009-08       Impact factor: 9.941

5.  Successful response to rituximab in two cases of acquired haemophilia refractory to standard-therapy.

Authors:  P Machado; J M Raya; T Martín; L Morabito; M L Brito; J M Rodríguez-Martín
Journal:  Int J Hematol       Date:  2008-04-15       Impact factor: 2.490

6.  Acquired haemophilia A complicating alemtuzumab therapy for multiple sclerosis.

Authors:  Georgia McCaughan; Jennifer Massey; Ian Sutton; Jennifer Curnow
Journal:  BMJ Case Rep       Date:  2017-12-05

7.  Acquired hemophilia A.

Authors:  Yadav Pandey; Dinesh Atwal; Manojna Konda; Arya Roy; Appalanaidu Sasapu
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-11-20

8.  Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A.

Authors:  Jisu Oh; Yeongmin Lim; Moon Ju Jang; Ji Young Huh; Midori Shima; Doyeun Oh
Journal:  Blood Res       Date:  2013-03-25

9.  Successful bypass surgery for esophageal carcinoma under adequate factor XIII/13 replacement therapy in a case of intractable autoimmune hemorrhaphilia due to anti-Factor XIII/13 antibodies.

Authors:  Minoru Kojima; Akitada Ichinose; Masayoshi Souri; Tsukasa Osaki; Hidetsugu Kawai; Jun Amaki; Hiroki Numata; Mitsuki Miyamoto; Daisuke Ogiya; Kosuke Tsuboi; Yoshiaki Ogawa; Soji Ozawa; Kiyoshi Ando
Journal:  Int J Hematol       Date:  2015-11-30       Impact factor: 2.490

10.  Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.

Authors:  S L Meeks; J F Healey; E T Parker; R T Barrow; P Lollar
Journal:  J Thromb Haemost       Date:  2009-01-24       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.